&nbsp;

AC-PACL(DD)+TRAS.pdf

Apr 2020

Document

AC-PACL(DD)+TRAS-FR.pdf

Apr 2020

Acute Lymphoblastic Leukemia: What to Expect During Intensive Chemotherapy Treatment

This page is for people newly diagnosed with ALL.

Guidelines and Advice

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Status: In-Review
ID: 3-22
Version: N/A

Apr 2020

Drug Submissions for Manufacturers

This page is for drug manufacturers who need information on the cancer drug submission process. Please do not mail cancer drug submissions to Ontario...

Document

DiagnosticMedicalSonographerWorksheet

May 2020

Document

DiagnosticImagingClinicalIndicationforScanandPriorityLevelExamples

May 2020

Document

DiagnosticImagingDefinitions

May 2020

Regimen

DHAP+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

ODB - General Benefit

dexamethasone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2020

Regimen

DCRBDOXO

Cancer Type:

Sarcoma,

Soft Tissue

Intent: Adjuvant, Curative, Palliative

Drugs Used:

dacarbazine,

DOXOrubicin

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

AZCTVENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

DEXAPOMA+ISAT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

New Drug Funding Program

Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Exceptional Access Program

pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria

Drugs Used: